Related Experiment Videos
Emerging strategies for drug development in motor neuron disease
1Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. sorenson.eric@mayo.edu
Abstract:
Until recently, attempts to identify disease-modifying treatments in motor neuron disease have largely failed. This was due to a lack of understanding of the disease pathogenesis and poor clinical trial design. Recent advances in the genetics of motor neuron disease and the maturation of tissue culture techniques have increased our understanding of the mechanisms of cell death in motor neuron disease. This has in turn led to better in vitro and transgenic animal models, allowing for a more systematic study of the disease process and analysis of potential therapeutic agents. With the advent of these models, motor neuron disease drug research has entered a new era. It is now possible to pursue mass screening of compounds in the in vitro models. Successful compounds in vitro can be advanced to the transgenic animal models. Once toxicity and potential therapeutic effects in animals are known, agents which remain promising can be taken to Phase I, II and III clinical trials. This will increase the likelihood of success and is more desirable than methods previously utilised. A hierarchical approach such as this will be even more important as multi-drug regimens are to be studied. The number of combinations for these multi-drug regimens becomes prohibitive without a screening method.
Insights
Recent advances in motor neuron disease (MND) research, including genetics and models, enable systematic drug screening. This hierarchical approach improves the identification of effective disease-modifying treatments for MND.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Previous attempts to find disease-modifying treatments for motor neuron disease (MND) were hindered by poor understanding of pathogenesis and clinical trial design.
- Recent breakthroughs in MND genetics and tissue culture have improved comprehension of cell death mechanisms.
Purpose of the Study:
- To outline a new era of drug research for motor neuron disease driven by advanced models.
- To describe a systematic, hierarchical approach for identifying and testing potential therapeutic agents for MND.
Main Methods:
- Utilizing in vitro models for mass screening of compounds.
- Advancing successful compounds from in vitro to transgenic animal models for toxicity and efficacy assessment.
- Progressing promising agents through Phase I, II, and III clinical trials.
Main Results:
- The development of better in vitro and transgenic animal models allows for more systematic study of MND.
- This systematic approach increases the likelihood of success in identifying effective therapeutic agents.
- Enables efficient screening of multi-drug regimens, overcoming combinatorial challenges.
Conclusions:
- Advanced models have revolutionized drug discovery for motor neuron disease.
- A hierarchical screening approach is crucial for efficient and successful development of new MND treatments.
- This methodology is essential for studying complex multi-drug regimens in MND therapy.